Lindsey Shapiro, PhD, science writer —

Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.

Articles by Lindsey Shapiro

Neurodegeneration and cognitive decline slow with Anavex 2-73

Anavex Life Sciences’ investigational oral therapy Anavex 2-73 (blarcamesine) significantly slows cognitive and functional decline in people with early Alzheimer’s disease, according to a new data analysis of a Phase 2b/3 clinical trial. The cognitive benefits were accompanied by a slower rate of brain shrinkage, a marker…

PrecivityAD test has guided clinical decision-making

The PrecivityAD blood test from C2N Diagnostics significantly influences clinicians’ decisions about whether to treat people with cognitive impairments for Alzheimer’s disease. C2N, which sponsored the recent study, believes those findings offer robust real-world evidence that blood biomarker testing in the clinic helps to guide treatment decisions…